These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 11139311

  • 1. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
    Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH.
    Br J Cancer; 2001 Jan 05; 84(1):42-7. PubMed ID: 11139311
    [Abstract] [Full Text] [Related]

  • 2. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
    Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O.
    Clin Cancer Res; 2000 Nov 05; 6(11):4416-21. PubMed ID: 11106262
    [Abstract] [Full Text] [Related]

  • 3. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Jan 05; 59(1):43-50. PubMed ID: 16680462
    [Abstract] [Full Text] [Related]

  • 4. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
    Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens JH.
    Clin Cancer Res; 1999 Nov 05; 5(11):3379-84. PubMed ID: 10589748
    [Abstract] [Full Text] [Related]

  • 5. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD, Baker SD, Denis LJ, Johnson T, Drengler R, Siu LL, Duchin K, Kuhn J, Rowinsky EK.
    Clin Cancer Res; 2000 Sep 05; 6(9):3459-68. PubMed ID: 10999729
    [Abstract] [Full Text] [Related]

  • 6. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
    Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JH.
    Cancer Chemother Pharmacol; 2001 Apr 05; 47(4):347-54. PubMed ID: 11345652
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Ten Bokkel Huinink WW, Beijnen JH.
    Br J Cancer; 2001 Nov 16; 85(10):1472-7. PubMed ID: 11720431
    [Abstract] [Full Text] [Related]

  • 11. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D.
    Cancer Chemother Pharmacol; 2007 Jun 16; 60(1):81-9. PubMed ID: 17031646
    [Abstract] [Full Text] [Related]

  • 12. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
    Park JH, Park JH, Hur HJ, Woo JS, Lee HJ.
    Eur J Pharm Sci; 2012 Feb 14; 45(3):296-301. PubMed ID: 22172604
    [Abstract] [Full Text] [Related]

  • 13. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
    Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K.
    Clin Cancer Res; 2005 Jul 01; 11(13):4843-50. PubMed ID: 16000582
    [Abstract] [Full Text] [Related]

  • 14. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
    van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH.
    Clin Cancer Res; 1998 Oct 01; 4(10):2293-7. PubMed ID: 9796957
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
    Yamamoto R, Kaneuchi M, Nishiya M, Todo Y, Takeda M, Okamoto K, Negishi H, Sakuragi N, Fujimoto S, Hirano T.
    Cancer Chemother Pharmacol; 2002 Aug 01; 50(2):137-42. PubMed ID: 12172979
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice.
    Hosten B, Abbara C, Petit B, Dauvin A, Bourasset F, Farinotti R, Gonin P, Bonhomme-Faivre L.
    Drug Metab Dispos; 2008 Aug 01; 36(8):1729-35. PubMed ID: 18508881
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
    Jamois C, Comets E, Mentré F, Marion S, Farinotti R, Bonhomme-Faivre L.
    Cancer Chemother Pharmacol; 2005 Jan 01; 55(1):61-71. PubMed ID: 15378273
    [Abstract] [Full Text] [Related]

  • 20. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR.
    Cancer; 2003 May 15; 97(10):2480-6. PubMed ID: 12733147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.